Cover Image
市場調查報告書

MediPoint:神經血管介入--全球市場分析與預測

MediPoint: Neurovascular Interventions - Global Analysis and Market Forecasts

出版商 GlobalData 商品編碼 298829
出版日期 內容資訊 英文 432 Pages
訂單完成後即時交付
價格
Back to Top
MediPoint:神經血管介入--全球市場分析與預測 MediPoint: Neurovascular Interventions - Global Analysis and Market Forecasts
出版日期: 2014年04月02日 內容資訊: 英文 432 Pages
簡介

全球神經血管介入以2位數的速度急速成長。神經介入技術與低侵入性治療技術急速進步,未來可治療的疾病也更多。神經血管介入市場分為血管堵塞、血管再生、機械除去血栓、進入/支援4項分類。

本報告針對全球腦血管疾病(頭蓋內動脈瘤/動靜脈畸形、動脈粥樣硬化)治療神經血管介入市場分析,提供疾病概要與市場構造、目前未滿足需求、主要市場促進、阻礙因素、今後市場機會、實驗中主要產品、全球整體主要10國市場動向(過去3年實績與今後7年預測值)、產品種類分類詳細動向、主要企業檔案,目錄介紹如下。

第1章 目錄

第2章 介紹

第3章 臨床結果

  • 疾病管理
    • 頭蓋內動脈瘤
    • 頭蓋內動靜脈畸形
    • 硬膜動靜脈瘺
    • 頭蓋內/頭蓋外動脈粥樣硬化
    • 腦中風
  • 治療方式
    • 概要
    • 醫藥/化學療法
    • 外科療法
    • 血管內療法

第4章 產業概要

  • 概況
  • 處理趨勢
    • 頭蓋內動脈瘤
    • 頭蓋內動靜脈畸形
    • 動脈粥樣硬化
    • 急性缺血性腦中風
  • 進入市場
    • 規範流程
    • 醫師瞭解、決策流程
    • 臨床診療的變化
    • 臨床資料不足
    • 地區級管理
    • 成本考量
    • 醫療費補償趨勢
  • 規範課題/回顧
  • 企業合併、收購(M&A)/主要合作(11件)
  • 經濟影響
    • 頭蓋內動脈瘤/動靜脈畸形的狀況
    • 中風的狀況
    • 腦血管疾病治療費

第5章 未滿足需求

  • 概要
  • 訓練、實績、醫師訓練指南需求
  • 臨床資料不足
  • 急性缺血發作時的管理改善
  • 處理複雜化外科療法
  • 手術夾的問題
  • 欠缺處理未破裂頭蓋內動脈瘤治療策略
  • 複雜形態、規模的動脈瘤有效治療法
  • 頭蓋內動靜脈畸形的治療困難
  • 球囊血管形成法相關課題
  • 神經血管支架相關課題
  • 雙重抗血小板凝集劑(DAPT)的複雜化
  • 醫藥療法的改善必要性
  • 進入緩和必要性

第6章 市場機會分析

  • 神經血管介入市場
  • 神經介入設備設計改善
  • 複雜頭蓋內動脈瘤/動靜脈畸形治療相關課題
  • 以多數患者為對象的治療法
  • 急性缺血患者的最佳治療法
  • 藥物洗脫設備的開發
  • 新興市場

第7章 市場促進因素與課題

  • 市場促進因素
    • 疾病率上昇
    • 血管內栓塞臨床結果的改善
    • 血管支架/球囊輔助栓塞治療法的改變
    • 可實施的複雜頭蓋內動脈瘤治療選擇
    • 為治療動脈瘤栓塞以外代替閉塞形成設備
    • 頭蓋內動靜脈畸形血管內堵塞
    • 頭蓋內動靜脈畸形治療的影像診斷
    • 頸動脈硬化性疾病的血管支架
    • 低調的血管支架設備
    • 機械除血栓設備再通率改善
    • 降低成本
    • 可獲得長期、有成本效率的資料
  • 市場課題
    • 神經介入處理、設備複雜性
    • 臨床資料不足
    • 治療費高昂
    • 醫療費補償額不足
    • 缺乏優秀的生物活性/覆蓋圈
    • 腦中風治療的代替方法
    • 規範問題:美國FDA與EC標示
    • 醫療費削減與醫療費補償
    • 可用的風險投資
    • 醫療設備的貨品稅

第8章 競爭力評價

  • 概要
  • 全球市場佔有率
  • 已上市製品(共29製品)

第9章 臨床實驗製品評價

  • 概要
  • 開發階段分類臨床實驗製品
  • 產品檔案(共12項製品)

第10章 治療分析

  • 概要
  • 矚目治療
    • 血管堵塞
    • 血流重建
    • 血管再生
    • 機械除血栓

第11章 現在、未來加入市場企業

  • 概要
  • 企業策略傾向
  • 企業檔案(30家)

第12章 市場未來展望

  • 部門分類預測
    • 血管堵塞設備市場
    • 血管再生設備市場
    • 機械除血栓設備市場
    • 進入/支援設備市場
  • 地區分類預測
    • 全體狀況
    • 美國
    • 歐洲主要5國
    • 南美

第13章 附錄

圖表一覽

目錄
Product Code: GDME0194MAR

The global neurovascular interventions market is a vast, double-digit market that consists of innovative and emerging technologies. Rapid advances in the field of neurovascular interventions and development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. The neurovascular interventions market consists of four device segments including embolization, revascularization, mechanicalthrombectomy and access/support devices.

Embolization devices including bare metal and bioactive/coated coils, aneurysm remodeling devices (stents and occlusion balloons), flow diversion devices and liquid embolic agents can be used to treat intracranial aneurysms and arteriovenous malformations (AVMs) and optimize outcomes. Low-profile stent and balloon systems can be used to revascularize plaque burdened arteries in the cerebrovasculature. Mechanical thrombectomy devices including distal and proximal devices and stent retrievers can improve recanalization rates and provide predictable outcomes in the setting of acute ischemic stroke (AIS). In addition, the next generation of access/support devices has been developed to improve navigation, trackability and flexibility as well as provide stable access, especially through tortuous anatomy.

This report focuses on the global neurovascular interventions market in the 10 major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, China, India, and Brazil) for treating cerebrovascular disease including intracranial aneurysms and AVMs, atherosclerotic disease, and AIS. The global neurovascular interventions market is determined for the 10 countries covered in this report and provides insight into the competitive landscape, the marketed and pipeline products, the current and emerging players and market analysis of the different device segments within the neurointerventional market. The report identifies the unmet needs in the market while providing an understanding of physicians' perceptions and decision-making processes in using neurointerventional devices; this report also evaluates the adoption of various neurointerventional devices in the future.

Highlights

Key Questions Answered

  • The neurovascular interventions market is expected to continue its growth through the forecast period. (Q).What are the primary patient segments, indications and different product offerings in the neurovascular interventions market?
  • Endovascular therapy for cerebrovascular applications has seen rapid development in materials research and new techniques for treatment. (Q).What specific technologies/device segments will drive the market ? (Q).What are the future trends and drivers for growth in the market?
  • Innovative technologies such as flow diverters and stent retrievers have been developed to treat challenging indications. (Q).Is flow diversion a viable alternative for patients with complex aneurysms? (Q).Will stent retrievers continue to be adopted widely in clinical practice in the future? (Q).Do we see pricing pressure in the neurointerventional devices?
  • Stenting and balloon angioplasty is primarily performed in the setting of carotid artery stenosis. (Q).What is the market potential for revascularization devices? (Q).What is the market outlook for endovascular stenting for atherosclerotic disease?
  • The top players in this market have developed a broad and comprehensive portfolio of neurointerventional devices for various cerebrovascular indications. (Q).What role do smaller players have in grabbing market share in the different global regions? (Q).Who are the key players in the neurovascular interventional market?

Scope

  • Overview of cerebrovascular disease, including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines and modalities.
  • Annualized total neurovascular interventions market revenue by device segment, annual cost of disease and neurointerventional devices adoption pattern and procedure data from 2011-2013 and forecast for seven years to 2020.
  • Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, evaluating market access in each region covered in the report, and implications of the neurovascular interventions market.
  • Pipeline analysis: Comprehensive data split across different stages of development, emerging trends and device designs in development.
  • Analysis of the current and future market competition in the global neurovascular interventions market. Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global neurovascular interventions market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global neurovascular interventions market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific neurovascular interventions market from 2011-2020.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst

3. Clinical Outcomes

  • 3.1. Disease Management
    • 3.1.1. Intracranial Aneurysms
    • 3.1.2. Intracranial Arteriovenous Malformations
    • 3.1.3. Dural Arteriovenous Fistulas
    • 3.1.4. Intracranial and Extracranial Atherosclerotic Disease
    • 3.1.5. Stroke
  • 3.2. Treatment Modalities
    • 3.2.1. Overview
    • 3.2.2. Medical/Chemical Therapy
    • 3.2.3. Surgical Therapy
    • 3.2.4. Endovascular Therapy

4. Industry Overview

  • 4.1. Overview
  • 4.2. Procedure Trends
    • 4.2.1. Intracranial Aneurysms
    • 4.2.2. Intracranial Arteriovenous Malformations
    • 4.2.3. Atherosclerotic Disease
    • 4.2.4. Acute Ischemic Stroke
  • 4.3. Market Access
    • 4.3.1. Regulatory Process
    • 4.3.2. Physician Perception and Decision Making Process
    • 4.3.3. Variations in Clinical Practice
    • 4.3.4. Lack of Clinical Data
    • 4.3.5. Regional-Level Control
    • 4.3.6. Cost-Considerations
    • 4.3.7. Reimbursement Trends
  • 4.4. Regulatory Issues/Recalls
    • 4.4.1. Regulatory Issues
    • 4.4.2. Product Recalls
  • 4.5. Mergers and Acquisitions/Key Partnerships
    • 4.5.1. Covidien and Nfocus Neuromedical
    • 4.5.2. Stryker Corporation and Surpass Medical
    • 4.5.3. Covidien and MindFrame
    • 4.5.4. Covidien and Reverse Medical Corporation
    • 4.5.5. Stryker Corporation and Boston Scientific Neurovascular
    • 4.5.6. Stryker Corporation and Concentric Medical
    • 4.5.7. Covidien and ev3
    • 4.5.8. Medtronic and Invatec
    • 4.5.9. Johnson & Johnson and Micrus Endovascular
    • 4.5.10. ev3 and Chestnut Medical Technologies
    • 4.5.11. Boston Scientific Corporation and Guidant Corporation
  • 4.6. Economic Impact
    • 4.6.1. Economic Impact of Intracranial Aneurysms and Arteriovenous Malformations
    • 4.6.2. Economic Impact of Stroke
    • 4.6.3. Treatment Costs of Cerebrovascular Disease

5. Unmet Needs

  • 5.1. Overview
  • 5.2. Need for Practice, Performance, and Physician Training Guidelines
  • 5.3. Lack of Clinical Data
  • 5.4. Improve Management of Acute Ischemic Stroke
  • 5.5. Address Complications of Surgical Therapy
  • 5.6. Addressing the Challenges of Surgical Clipping
  • 5.7. Lack of Optimal Treatment Strategy for Unruptured Intracranial Aneurysms
  • 5.8. Need for Effective Therapies for Complex Aneurysm Morphologies and Sizes
  • 5.9. Difficulty in Treating Intracranial Arteriovenous Malformations
  • 5.10. Eliminating Mechanisms of Failure with Balloon Angioplasty
  • 5.11. Addressing Challenges of Neurovascular Stenting
    • 5.11.1. Risk of Post-Procedural Complications
    • 5.11.2. In-Stent Restenosis
    • 5.11.3. Stent Navigation
  • 5.12. Complications of Dual Antiplatelet Therapy
  • 5.13. Need to Improve Medical Therapy
  • 5.14. Improve Ease of Access

6. Market Opportunity Analysis

  • 6.1. Neurovascular Interventions Market
  • 6.2. Improve Neurointerventional Device Design
  • 6.3. Challenges in Treating Complex Intracranial Aneurysms and Arteriovenous Malformations
    • 6.3.1. Intracranial Aneurysms
    • 6.3.2. Intracranial Arteriovenous Malformations
  • 6.4. Target Challenging Patient Populations
  • 6.5. Optimize Care for Acute Ischemic Stroke Patients
  • 6.6. Development of Drug-Eluting Devices
  • 6.7. Emerging Markets

7. Market Drivers and Barriers

  • 7.1. Market Drivers
    • 7.1.1. Rising Prevalence of Disease
    • 7.1.2. Improved Clinical Outcomes with Endovascular Coiling
    • 7.1.3. Remodeling Techniques with Stent and Balloon-Assisted Coiling
    • 7.1.4. Viable Therapeutic Option for Challenging/Complex Intracranial Aneurysms
    • 7.1.5. Alternative Non-Coiling Embolization Devices for Aneurysm Treatment
    • 7.1.6. Endovascular Embolization of Intracranial Arteriovenous Malformations
    • 7.1.7. Imaging Assessment for Intracranial Arteriovenous Malformation Treatment
    • 7.1.8. Stenting for Carotid Atherosclerotic Disease
    • 7.1.9. Low-Profile Stent Systems
    • 7.1.10. Improved Recanalization Rates with Mechanical Thrombectomy Devices
    • 7.1.11. Cost Savings
    • 7.1.12. Availability of Long-Term and Cost-Effective Data
  • 7.2. Market Barriers
    • 7.2.1. Complications of Neurointerventional Procedures and Devices
    • 7.2.2. Lack of Clinical Data
    • 7.2.3. High Cost of Treatment
    • 7.2.4. Lack of Reimbursement
    • 7.2.5. Lack of Superiority of Bioactive/Coated Coils
    • 7.2.6. Alternative Technologies for Stroke Therapy
    • 7.2.7. Regulatory Challenges: US Food and Drug Administration and European Conformity Mark
    • 7.2.8. Healthcare Cost-Cutting and Reimbursement
    • 7.2.9. Availability of Venture Capital
    • 7.2.10. Medical Device Excise Tax

8. Competitive Assessment

  • 8.1. Overview
  • 8.2. Global Market Share
  • 8.3. Marketed Products
    • 8.3.1. Aachen Resonance
    • 8.3.2. Abbott Vascular
    • 8.3.3. Acandis
    • 8.3.4. B. Braun
    • 8.3.5. BALT Extrusion
    • 8.3.6. Blockade Medical
    • 8.3.7. Boston Scientific Corporation
    • 8.3.8. Contego Medical
    • 8.3.9. Cook Medical
    • 8.3.10. Covidien
    • 8.3.11. Gardia Medical
    • 8.3.12. Gore Medical
    • 8.3.13. InspireMD
    • 8.3.14. ITGI Medical
    • 8.3.15. Johnson & Johnson
    • 8.3.16. Medikit
    • 8.3.17. Medtronic
    • 8.3.18. Merlin MD
    • 8.3.19. MicroPort Scientific Corporation
    • 8.3.20. Minvasys
    • 8.3.21. Neuravi
    • 8.3.22. Optimed
    • 8.3.23. Penumbra
    • 8.3.24. Phenox GmbH
    • 8.3.25. Reverse Medical
    • 8.3.26. Sequent Medical
    • 8.3.27. Stryker Neurovascular Intervention
    • 8.3.28. Terumo Corporation
    • 8.3.29. Valor Medical

9. Pipeline Assessment

  • 9.1. Overview
  • 9.2. Pipeline by Stage of Development
  • 9.3. Product Profiles
    • 9.3.1. Aneurysm Occlusion Saddle
    • 9.3.2. Ballstent Microcatheter
    • 9.3.3. Blood Clot Removing Device
    • 9.3.4. EKOS' EkoSonic Small Vessel Endovascular System
    • 9.3.5. Flow-Diverting Thin-Film Nitinol Covered Stent
    • 9.3.6. Ischemic Stroke System
    • 9.3.7. Janjua Aneurysm Net
    • 9.3.8. Multilayer Aneurysm Repair System
    • 9.3.9. NAVIMAX
    • 9.3.10. Palmaz Scientific Stents
    • 9.3.11. Silk Road System
    • 9.3.12. Transcranial Thrombectomy Catheter

10. Clinical Trial Analysis

  • 10.1. Overview
  • 10.2. Clinical Trials to Watch
    • 10.2.1. Embolization
    • 10.2.2. Flow Diversion
    • 10.2.3. Revascularization
    • 10.2.4. Mechanical Thrombectomy

11. Current and Future Players

  • 11.1. Overview
  • 11.2. Trends in Corporate Strategy
  • 11.3. Company Profiles
    • 11.3.1. BALT Extrusion
    • 11.3.2. Covidien
    • 11.3.3. Johnson & Johnson
    • 11.3.4. Penumbra
    • 11.3.5. Stryker Corporation
    • 11.3.6. Terumo Corporation
    • 11.3.7. Abbott Vascular
    • 11.3.8. Boston Scientific Corporation
    • 11.3.9. Cook Medical
    • 11.3.10. Gore Medical
    • 11.3.11. Medtronic
    • 11.3.12. Aachen Resonance
    • 11.3.13. Acandis
    • 11.3.14. B. Braun
    • 11.3.15. Blockade Medical
    • 11.3.16. Contego Medical
    • 11.3.17. Gardia Medical
    • 11.3.18. InspireMD
    • 11.3.19. ITGI Medical
    • 11.3.20. Medikit
    • 11.3.21. Merlin MD
    • 11.3.22. MicroPort Scientific Corporation
    • 11.3.23. Minvasys
    • 11.3.24. Neuravi
    • 11.3.25. Optimed
    • 11.3.26. Phenox GmBH
    • 11.3.27. Reverse Medical
    • 11.3.28. Sequent Medical
    • 11.3.29. Valor Medical
    • 11.3.30. Other Companies

12. Market Outlooks

  • 12.1. By Market Segment
    • 12.1.1. Embolization Device Market
    • 12.1.2. Revascularization Device Market
    • 12.1.3. Mechanical Thrombectomy Device Market
    • 12.1.4. Access/Support Device Market
  • 12.2. By Geography
    • 12.2.1. Global Overview
    • 12.2.2. United States
    • 12.2.3. The Five European Union Markets
    • 12.2.4. The Asia-Pacific Region
    • 12.2.5. South America

13. Appendix

  • 13.1. Bibliography
  • 13.2. Abbreviations
  • 13.3. Report Methodology
    • 13.3.1. Overview
    • 13.3.2. Coverage
    • 13.3.3. Secondary Research
  • 13.4. Physicians and Specialists Included in this Study
    • 13.4.1. Vivek Gupta, MD
    • 13.4.2. Zsolt Kulscar, MD, PhD
    • 13.4.3. Salvatore Mangiafico, MD
    • 13.4.4. Thanh Nguyen, MD, FRCPc
    • 13.4.5. Eduardo Wajnberg, MD
    • 13.4.6. Phil White, MD
    • 13.4.7. Osama O Zaidat, MD, MS, FAAN, FAHA
  • 13.5. Primary Research
    • 13.5.1. Primary Research - Key Opinion Leader Interviews
    • 13.5.2. Expert Panel Validation
  • 13.6. Forecasting Methodology
  • 13.7. About the Authors
    • 13.7.1. Analysts
    • 13.7.2. Global Head of Healthcare
  • 13.8. About MediPoint
  • 13.9. About GlobalData
  • 13.10. Disclaimer

List of Tables

  • Table 1: Complications of Cerebral Artery Bypass Surgery
  • Table 2: Types of Cerebral Embolic Protection Devices
  • Table 3: Medicare National Average of Inpatient Hospital Payment for Neurovascular Interventions, 2013-2014
  • Table 4: Reimbursement Classification of Medical Devices in Japan
  • Table 5: US Mean Hospital Costs* for Treating Cerebrovascular Disease, 2011-2020 ($US)
  • Table 6: Aachen Resonance Neurovascular Intervention Marketed Product
  • Table 7: Aachen Resonance Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 8: Abbott Vascular Neurovascular Intervention Marketed Products
  • Table 9: Abbott Vascular Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 10: Acandis Neurovascular Intervention Marketed Products
  • Table 11: Acandis Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 12: B. Braun Neurovascular Intervention Marketed Product
  • Table 13: B. Braun Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 14: BALT Extrusion Neurovascular Intervention Marketed Products
  • Table 15: BALT Extrusion Neurovascular Intervention Marketed Access Products
  • Table 16: BALT Extrusion Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 17: Blockade Medical Neurovascular Intervention Marketed Product
  • Table 18: Blockade Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 19: Boston Scientific Neurovascular Intervention Marketed Products
  • Table 20: Boston Scientific Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 21: Contego Medical Neurovascular Intervention Marketed Product
  • Table 22: Contego Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 23: Cook Medical Neurovascular Intervention Marketed Products
  • Table 24: Cook Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 25: Covidien Neurovascular Interventional Marketed Products
  • Table 26: Covidien Neurovascular Intervention Marketed Access Products
  • Table 27: Covidien Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 28: Gardia Medical Neurovascular Intervention Marketed Product
  • Table 29: Gardia Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 30: Gore Medical Neurovascular Intervention Marketed Products
  • Table 31: Gore Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 32: InspireMD Neurovascular Intervention Marketed Product
  • Table 33: InspireMD Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 34: ITGI Medical Neurovascular Intervention Marketed Product
  • Table 35: ITGI Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 36: Codman Neurovascular Marketed Embolization Products
  • Table 37: Codman Neurovascular Marketed Mechanical Thrombectomy and Access Products
  • Table 38: Codman Neurovascular's (Codman & Shurtleff) Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 39: Cordis Corporation Marketed Neurointerventional Products
  • Table 40: Cordis Corporation Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 41: Medikit Neurovascular Intervention Marketed Products
  • Table 42: Medikit Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 43: Medtronic Neurovascular Intervention Marketed Products
  • Table 44: Medtronic Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 45: Merlin MD Neurovascular Intervention Marketed Product
  • Table 46: Merlin MD Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 47: MicroPort Scientific Corporation Neurovascular Intervention Marketed Products
  • Table 48: MicroPort Scientific Corporation Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 49: Minvasys Neurovascular Intervention Marketed Product
  • Table 50: Minvasys Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 51: Neuravi Neurovascular Intervention Marketed Product
  • Table 52: Neuravi Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 53: Optimed Neurovascular Intervention Marketed Products
  • Table 54: Optimed Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 55: Penumbra Neurovascular Intervention Marketed Products
  • Table 56: Penumbra Marketed Neurovascular Access Products
  • Table 57: Penumbra Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 58: Phenox GmbH Neurovascular Intervention Marketed Products
  • Table 59: Phenox GmbH Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 60: Reverse Medical Neurovascular Intervention Marketed Products
  • Table 61: Reverse Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 62: Sequent Medical Neurovascular Intervention Marketed Products
  • Table 63: Sequent Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 64: Stryker Neurovascular Intervention Marketed Products
  • Table 65: Stryker Neurovascular Intervention Marketed Mechanical Thrombectomy and Access Products
  • Table 66: Stryker Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 67: Terumo Europe N.V. and Terumo Interventional Systems Marketed Neurointerventional Products
  • Table 68: Terumo Corporation Neurovascular Product Portfolio SWOT Analysis, 2014
  • Table 69: MicroVention Neurovascular Intervention Marketed Products
  • Table 70: MicroVention Marketed Neurovascular Access Products
  • Table 71: MicroVention Neurovascular Product Portfolio SWOT Analysis, 2014
  • Table 72: Valor Medical Neurovascular Intervention Marketed Products
  • Table 73: Valor Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 74: Global Neurovascular Interventions Pipeline Products
  • Table 75: Aneurysm Occlusion Saddle SWOT Analysis, 2014
  • Table 76: EKOS EkoSonic SV System SWOT Analysis, 2014
  • Table 77: Flow-Diverting Thin-Film Nitinol Covered Stent SWOT Analysis, 2014
  • Table 78: Janjua Aneurysm Net SWOT Analysis, 2014
  • Table 79: Multilayer Aneurysm Repair System SWOT Analysis, 2014
  • Table 80: NAVIMAX SWOT Analysis, 2014
  • Table 81: Palmaz Scientific Stents SWOT Analysis, 2014
  • Table 82: Silk Road System SWOT Analysis, 2014
  • Table 83: BALT Extrusion Company Profile
  • Table 84: BALT Extrusion Neurovascular Intervention Marketed Products
  • Table 85: BALT Extrusion SWOT Analysis, 2014
  • Table 86: Covidien Company Profile
  • Table 87: Covidien Neurovascular Intervention Marketed Products
  • Table 88: Covidien SWOT Analysis, 2014
  • Table 89: Codman & Shurtleff Company Profile
  • Table 90: Codman & Shurtleff Neurovascular Intervention Marketed Products
  • Table 91: Codman & Shurtleff SWOT Analysis, 2014
  • Table 92: Cordis Corporation Company Profile
  • Table 93: Cordis Corporation Neurovascular Intervention Marketed Products
  • Table 94: Cordis Corporation SWOT Analysis, 2014
  • Table 95: Penumbra Company Profile
  • Table 96: Penumbra Neurovascular Intervention Marketed Products
  • Table 97: Penumbra SWOT Analysis, 2014
  • Table 98: Stryker Corporation Company Profile
  • Table 99: Stryker Corporation Neurovascular Intervention Marketed Products
  • Table 100: Stryker Corporation SWOT Analysis, 2014
  • Table 101: Terumo Corporation Company Profile
  • Table 102: Terumo Europe N.V. and Terumo Interventional Systems Neurovascular Intervention Marketed Products
  • Table 103: MicroVention Neurovascular Intervention Marketed Products
  • Table 104: Terumo Corporation SWOT Analysis, 2014
  • Table 105: Abbott Vascular Company Profile
  • Table 106: Abbott Vascular Neurovascular Intervention Marketed Products
  • Table 107: Abbott Vascular SWOT Analysis, 2014
  • Table 108: Boston Scientific Corporation Company Profile
  • Table 109: Boston Scientific Neurovascular Intervention Marketed Products
  • Table 110: Boston Scientific Corporation SWOT Analysis, 2014
  • Table 111: Cook Medical Company Profile
  • Table 112: Cook Medical Neurovascular Intervention Marketed Products
  • Table 113: Cook Medical SWOT Analysis, 2014
  • Table 114: Gore Medical Company Profile
  • Table 115: Gore Medical Neurovascular Intervention Marketed Products
  • Table 116: Gore Medical SWOT Analysis, 2014
  • Table 117: Medtronic Company Profile
  • Table 118: Medtronic Neurovascular Intervention Marketed Products
  • Table 119: Medtronic SWOT Analysis, 2014
  • Table 120: Aachen Resonance Company Profile
  • Table 121: Aachen Resonance Neurovascular Intervention Marketed Product
  • Table 122: Aachen Resonance SWOT Analysis, 2014
  • Table 123: Acandis Company Profile
  • Table 124: Acandis Neurovascular Intervention Marketed Products
  • Table 125: Acandis SWOT Analysis, 2014
  • Table 126: B. Braun Company Profile
  • Table 127: B. Braun Neurovascular Intervention Marketed Product
  • Table 128: B. Braun SWOT Analysis, 2014
  • Table 129: Blockade Medical Company Profile
  • Table 130: Blockade Medical Neurovascular Intervention Marketed Product
  • Table 131: Blockade Medical SWOT Analysis, 2014
  • Table 132: Contego Medical Company Profile
  • Table 133: Contego Medical Neurovascular Intervention Marketed Product
  • Table 134: Contego Medical SWOT Analysis, 2014
  • Table 135: Gardia Medical Company Profile
  • Table 136: Gardia Medical Neurovascular Intervention Marketed Product
  • Table 137: Gardia Medical SWOT Analysis, 2014
  • Table 138: InspireMD Company Profile
  • Table 139: InspireMD Neurovascular Intervention Marketed Product
  • Table 140: InspireMD SWOT Analysis, 2014
  • Table 141: ITGI Medical Company Profile
  • Table 142: ITGI Medical Neurovascular Intervention Marketed Product
  • Table 143: ITGI Medical SWOT Analysis, 2014
  • Table 144: Medikit Company Profile
  • Table 145: Medikit Neurovascular Intervention Marketed Products
  • Table 146: Medikit SWOT Analysis, 2014
  • Table 147: Merlin MD Company Profile
  • Table 148: Merlin MD Neurovascular Intervention Marketed Product
  • Table 149: Merlin MD SWOT Analysis, 2014
  • Table 150: MicroPort Scientific Corporation Company Profile
  • Table 151: MicroPort Scientific Corporation Neurovascular Intervention Marketed Products
  • Table 152: MicroPort Scientific Corporation SWOT Analysis, 2014
  • Table 153: Minvasys Company Profile
  • Table 154: Minvasys Neurovascular Intervention Marketed Product
  • Table 155: Minvasys SWOT Analysis, 2014
  • Table 156: Neuravi Company Profile
  • Table 157: Neuravi Neurovascular Intervention Marketed Product
  • Table 158: Neuravi SWOT Analysis, 2014
  • Table 159: Optimed Company Profile
  • Table 160: Optimed Neurovascular Intervention Marketed Products
  • Table 161: Optimed SWOT Analysis, 2014
  • Table 162: Phenox GmBH Company Profile
  • Table 163: Phenox GmbH Neurovascular Intervention Marketed Products
  • Table 164: Phenox GmBH SWOT Analysis, 2014
  • Table 165: Reverse Medical Company Profile
  • Table 166: Reverse Medical Neurovascular Intervention Marketed Products
  • Table 167: Reverse Medical SWOT Analysis, 2014
  • Table 168: Sequent Medical Company Profile
  • Table 169: Sequent Medical Neurovascular Intervention Marketed Products
  • Table 170: Sequent Medical SWOT Analysis, 2014
  • Table 171: Valor Medical Company Profile
  • Table 172: Valor Medical Neurovascular Intervention Marketed Products
  • Table 173: Valor Medical SWOT Analysis, 2014
  • Table 174: Other Companies in the Neurovascular Intervention Market, 2014
  • Table 175: Global Embolization Device Market ($m) Forecast, 2011-2020
  • Table 176: Global Revascularization Device Market ($m) Forecast, 2011-2020
  • Table 177: Global Mechanical Thrombectomy Device Market ($m) Forecast, 2011-2020
  • Table 178: Global Access/Support Device Market ($m) Forecast, 2011-2020
  • Table 179: Neurovascular Interventions Market Sales ($m) Forecast for the US, 2011-2020
  • Table 180: Neurovascular Interventions Market Sales ($m) Forecast for France, 2011-2020
  • Table 181: Neurovascular Interventions Market Sales ($m) Forecast for Germany, 2011-2020
  • Table 182: Neurovascular Interventions Market Sales ($m) Forecast for Italy, 2011-2020
  • Table 183: Neurovascular Interventions Market Sales ($m) Forecast for Spain, 2011-2020
  • Table 184: Neurovascular Interventions Market Sales ($m) Forecast for the UK, 2011-2020
  • Table 185: Neurovascular Interventions Market Sales ($m) Forecast for Japan, 2011-2020
  • Table 186: Neurovascular Interventions Market Sales ($m) Forecast for China, 2011-2020
  • Table 187: Neurovascular Interventions Market Sales ($m) Forecast for India, 2011-2020
  • Table 188: Neurovascular Interventions Market Sales ($m) Forecast for Brazil, 2011-2020

List of Figures

  • Figure 1: Treatment Modalities - Neurovascular Interventions
  • Figure 2: Types of Stents Used for Neurovascular Interventions
  • Figure 3: Embolization Procedure Volume for Treating Intracranial Aneurysms, US, 2011-2020
  • Figure 4: Embolization Procedure Volume for Treating Intracranial Aneurysms, 5EU, 2011-2020
  • Figure 5: Embolization Procedure Volume for Treating Intracranial Aneurysms, APAC, 2011-2020
  • Figure 6: Embolization Procedure Volume for Treating Intracranial Aneurysms, South America, 2011-2020
  • Figure 7: Embolization Procedure Volume for Treating Intracranial Arteriovenous Malformations, Global, 2011-2020
  • Figure 8: Revascularization Procedure Volume for Treating Atherosclerotic Disease, US, 2011-2020
  • Figure 9: Revascularization Procedure Volume for Treating Atherosclerotic Disease, 5EU, 2011-2020
  • Figure 10: Revascularization Procedure Volume for Treating Atherosclerotic Disease, APAC, 2011-2020
  • Figure 11: Revascularization Procedure Volume for Treating Atherosclerotic Disease, South America, 2011-2020
  • Figure 12: Mechanical Thrombectomy Procedure Volume for Treating Acute Ischemic Stroke, US, 2011-2020
  • Figure 13: Mechanical Thrombectomy Procedure Volume for Treating Acute Ischemic Stroke, 5EU, 2011-2020
  • Figure 14: Mechanical Thrombectomy Procedure Volume for Treating Acute Ischemic Stroke, APAC, 2011-2020
  • Figure 15: Mechanical Thrombectomy Procedure Volume for Treating Acute Ischemic Stroke, South America, 2011-2020
  • Figure 16: US Mean Hospital Costs* for Treating Intracranial Aneurysms and Arteriovenous Malformations, 2011-2020 ($US)
  • Figure 17: US Mean Hospital Costs* for Treating Extracranial and Intracranial Atherosclerotic Disease, 2011-2020 ($US)
  • Figure 18: US Mean Hospital Costs* for Treating Stroke, 2011-2020 ($US)
  • Figure 19: Global Neurointerventional Market Distribution, 2013
  • Figure 20: Global Neurovascular Interventions Pipeline Products by Stage of Development, 2014
  • Figure 21: Global Neurovascular Interventions Market ($bn) for Treating Cerebrovascular Disease, 2011-2020
  • Figure 22: Distribution of Percentage of Patients Treated for Cerebrovascular Disease, Global, 2013
  • Figure 23: Global Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 24: Global Embolization Device Market Distribution, 2013 and 2020
  • Figure 25: Global Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 26: Global Revascularization Device Market Distribution, 2013 and 2020
  • Figure 27: Global Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 28: Global Mechanical Thrombectomy Device Market Distribution, 2013 and 2020
  • Figure 29: Global Access/Support Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 30: Global Access/Support Device Market Distribution, 2013 and 2020
  • Figure 31: Global Neurovascular Interventions Market Revenue ($bn), 2013 and 2020
  • Figure 32: US Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 33: US Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 34: US Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 35: US Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 36: US Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 37: French Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 38: French Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 39: French Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 40: French Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 41: French Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 42: German Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 43: German Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 44: German Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 45: German Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 46: German Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 47: Italian Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 48: Italian Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 49: Italian Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 50: Italian Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 51: Italian Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 52: Spanish Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 53: Spanish Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 54: Spanish Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 55: Spanish Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 56: Spanish Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 57: UK Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 58: UK Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 59: UK Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 60: UK Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 61: UK Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 62: Japanese Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 63: Japanese Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 64: Japanese Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 65: Japanese Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 66: Japanese Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 67: Chinese Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 68: Chinese Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 69: Chinese Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 70: Chinese Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 71: Chinese Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 72: Indian Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 73: Indian Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 74: Indian Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 75: Indian Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 76: Indian Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 77: Brazilian Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 78: Brazilian Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 79: Brazilian Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 80: Brazilian Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 81: Brazilian Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
Back to Top